Bondronate

Country of origin - Germany, Hoffmann-La Roche Ltd, produced by Roche Diagnostics GmbH Germany
Pharm-Group - Antiosteoporosis agents - biosphosphonates

Manufacturers - Boehringer Mannheim (Germany), Hoffmann-La Roche Ltd, produced by Roche Diagnostics GmbH (Germany)
International name - Ibandronic acid
Dosage forms - solution for infusion, solution for infusion 1 mg/ml, concentrate for the preparation of infusion solution 1 mg/ml
Composition - Active ingredient - Ibandronate.

Indications for use - Humoral tumor hypercalcemia (pseudohyperparathyroidism) in squamous cell cancer of the lungs, kidneys, genitourinary tract and some other malignant neoplasms; hypercalcemia caused by bone destruction in paraproteinemic hemoblastoses, lymphomas or metastatic breast cancer and a number of other solid malignant tumors in the bone; postmenopausal osteoporosis.

Contraindications - Hypersensitivity, increased creatinine levels, prostaglandin bronchial asthma, pregnancy, breastfeeding (cessation of breastfeeding is mandatory).

Side effects - Increased body temperature, flu-like syndrome (fever, chills, myalgia, ossalgia), decreased renal excretion of calcium, hypocalcemia, decreased levels of inorganic phosphorus, dyspeptic disorders, bronchospastic reactions.

Interaction - Aminoglycosides increase the risk of developing hypocalcemia. Chemically incompatible with calcium-containing solutions.

Overdose - Symptoms: clinically significant hypocalcemia (convulsions, Trousseau, Chvostek, Weiss, Schlesinger symptoms, prolongation of the QT interval with isoelectric ST interval), renal failure, impaired liver function. Treatment: administration of calcium gluconate, hemodialysis.

Special instructions - During treatment, regular monitoring of the levels of calcium, magnesium, phosphorus and creatinine in the blood serum is necessary.

Literature - Encyclopedia of Medicines 2004